Treatment of comorbidities of chronic daily headache

Current Treatment Options in Neurology

Volumn 10, Issue 1, 2008, Pages 36-43

  Ashina, Sait ^a   Lipton, Richard B ^a   Bigal, Marcelo E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BUTALBITAL; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; DECONGESTIVE AGENT; DEXAMETHASONE; DIHYDROERGOTAMINE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHENOBARBITAL; PLACEBO; PREDNISONE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; STEROID; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANXIETY; CHRONIC DAILY HEADACHE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DETOXIFICATION; DIET THERAPY; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FEEDBACK SYSTEM; HEALTH CARE NEED; HEREDITY; HIGH RISK PATIENT; HUMAN; LIFE STRESS; MAJOR DEPRESSION; MENTAL DISEASE; MIGRAINE; NOSE CONGESTION; OBESITY; PATIENT SATISFACTION; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; QUALITY OF LIFE; RELAXATION TRAINING; REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SLEEP APNEA SYNDROME; SMOKING CESSATION; SNORING; SYMPTOMATOLOGY; TREATMENT PLANNING; UVULOPALATOPHARYNGOPLASTY; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 38749084119     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0005-1     Document Type: Review

References (62)

1. Lipton RB, Pan J: Is migraine a progressive brain disease? JAMA 2004, 291:493-494.
2. Scher AI, Stewart WF, Liberman J, Lipton RB: Prevalence of frequent headache in a population sample. Headache 1998, 38:497-506.
3. Castillo J, Munoz P, Guitera V, Pascual J: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190-196.
4. Katsarava Z, Schneeweiss S, Kurth T, et al.: Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004, 62:788-790.
5. Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
6. Burstein R, Collins B, Jakubowski M: Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55:19-26.
7. Couch JR, Lipton RB, Stewart WF, Scher AI: Head or neck injury increases the risk of chronic daily headache. A population-based study. Neurology 2007, 69:1169-1177.
8. Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81-89.
9. Bigal ME, Sheftell FD, Rapoport AM, et al.: Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002, 42:575-581.
10. Bigal ME, Lipton RB: Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006, 67:252-257.
11. Juang KD, Wang SJ, Fuh JL, et al.: Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000, 40:818-823.
12. Peterlin BL, Ward T, Lidicker J, Levin M: A retrospective, comparative study on the frequency of abuse in migraine and chronic daily headache. Headache 2007, 47:397-401.
13. Scher AI, Stewart WF, Lipton RB: Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004, 63:2022-2027.
14. Tietjen GE, Brandes JL, Digre KB, et al.: High prevalence of somatic symptoms and depression in women with disabling chronic headache. Neurology 2007, 68:134-140.
15. Zed PJ, Loewen PS, Robinson G: Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999, 33:61-72.
16. Wang SJ, Fuh JL, Lu SR, et al.: Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000, 54:314-319.
17. Lu SR, Fuh JL, Chen WT, et al.: Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 2001, 21:980-986.
18. Bigal ME, Liberman JN, Lipton RB: Obesity and migraine: a population study. Neurology 2006, 66:545-550.
19. Bigal ME, Lipton RB, Holland PR, Goadsby PJ: Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007, 68:1851-1861.
20. Jennum P, Hein HO, Suadicani P, Gyntelberg F: Headache and cognitive dysfunctions in snorers. A cross-sectional study of 3323 men aged 54 to 74 years: the Copenhagen Male Study. Arch Neurol 1994, 51:937-942.
21. Ulfberg J, Carter N, Talback M, Edling C: Headache, snoring and sleep apnoea. J Neurol 1996, 243:621-625.
22. Scher AI, Lipton RB, Stewart WF: Habitual snoring as a risk factor for chronic daily headache. Neurology 2003, 60:1366-1368.
23. Verri AP, Proietti CA, Galli C, et al.: Psychiatric comorbidity in chronic daily headache. Cephalalgia 1998, 18(Suppl 21):45-49.
24. Couch JR, Ziegler DK, Hassanein RS: Evaluation of the relationship between migraine headache and depression. Headache 1975, 15:41-50.
25. Patel NV, Bigal ME, Kolodner KB, et al.: Prevalence and impact of migraine and probable migraine in a health plan. Neurology 2004, 63:1432-1438.
26. Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102-106.
27. McWilliams LA, Goodwin RD, Cox BJ: Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004, 111:77-83.
28. Merikangas KR, Angst J, Isler H: Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry 1990, 47:849-853.
29. Breslau N, Schultz LR, Stewart WF, et al.: Headache types and panic disorder: directionality and specificity. Neurology 2001, 56:350-354.
30. Maizels M, Burchette R: Somatic symptoms in headache patients: the influence of headache diagnosis, frequency, and comorbidity. Headache 2004, 44:983-993.
31. Zwart JA, Dyb G, Hagen K, et al.: Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003, 61:160-164.
32. Bigal ME, Rapoport AM, Sheftell FD, et al.: Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia 2004, 24:483-490.
33. Silverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992, 327:1109-1114.
34. Bahra A, Walsh M, Menon S, Goadsby PJ: Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003, 43:179-190.
35. Wilkinson SM, Becker WJ, Heine JA: Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 2001, 41:303-309.
36. Zeeberg P, Olesen J, Jensen R: Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006, 26:1192-1198.
37. Pini LA, Cicero AF, Sandrini M: Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001, 21:878-883.
38. Headache Classification Subcommittee, International Headache Society: The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004, 24(Suppl 1):9-160.
39. James WP, Astrup A, Finer N, et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356:2119-2125.
40. Bray GA, Ryan DH, Gordon D, et al.: A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996, 4:263-270.
41. Sjostrom L, Rissanen A, Andersen T, et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352:167-172.
42. Silberstein SD, Hulihan J, Karim MR, et al.: Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/ without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 2006, 28:1002-1011.
43. Brandes JL, Saper JR, Diamond M, et al.: Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291:965-973.
44. Storey JR, Calder CS, Hart DE, Potter DL: Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001, 41:968-975.
45. Maggioni F, Ruffatti S, Dainese F, et al.: Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain 2005, 6:322-324.
46. Berilgen MS, Bulut S, Gonen M, et al.: Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005, 25:1048-1053.
47. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA: Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002, 42:510-514.
48. Freitag FG, Diamond S, Diamond ML, Urban GJ: Divalproex in the long-term treatment of chronic daily headache. Headache 2001, 41:271-278.
49. Parker RJ, Hardinge M, Jeffries C: Snoring [review]. BMJ 2005, 331:1063.
50. Friedman M, Lin HC, Gurpinar B, Joseph NJ: Minimally invasive single-stage multilevel treatment for obstructive sleep apnea/hypopnea syndrome. Laryngoscope 2007, 117:1859-1863.
51. Walker-Engstrom ML, Tegelberg A, Wilhelmsson B, Ringqvist I: 4-year follow-up of treatment with dental appliance or uvulopalatopharyngoplasty in patients with obstructive sleep apnea: a randomized study. Chest 2002, 121:739-746.
52. Loredo JS, Ancoli-Israel S, Kim EJ, et al.: Effect of continuous positive airway pressure versus supplemental oxygen on sleep quality in obstructive sleep apnea: a placebo-CPAP-controlled study. Sleep 2006, 29:564-571.
53. Verse T, Pirsig W, Stuck BA, et al.: Recent developments in the treatment of obstructive sleep apnea. Am J Respir Med 2003, 2:157-168.
54. Penzien DB, Rains JC, Andrasik F: Behavioral management of recurrent headache: three decades of experience and empiricism. Appl Psychophysiol Biofeedback 2002, 27:163-181.
55. Grazzi L, Andrasik F, D'Amico D, et al.: Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002, 42:483-490.
56. Couch JR, Hassanein RS: Amitriptyline in migraine prophylaxis. Arch Neurol 1979, 36:695-699.
57. Katsarava Z, Muessig M, Dzagnidze A, et al.: Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005, 25:12-15.
58. Trucco M, Meineri P, Ruiz L: Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain 2005, 6:334-337.
59. Mei D, Ferraro D, Zelano G, et al.: Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 2006, 29:269-275.
60. Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME: Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. Headache 2005, 45:1400-1406.
61. Bonuccelli U, Nuti A, Lucetti C, et al.: Amitriptyline and dexamethasone combined treatment in drug-induced headache. Cephalalgia 1996, 16:198-200.
62. Loder E, Biondi D: Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds. Headache 2003, 43:904-909.